Nacolomab tafenatox
Nacolomab tafenatox (pronunciation: na-co-lo-mab ta-fe-na-tox) is a therapeutic antibody used in the treatment of certain types of cancer. It is a monoclonal antibody that has been conjugated with a toxin, specifically the Pseudomonas exotoxin.
Etymology
The name "Nacolomab tafenatox" is derived from the following components: "Naco" refers to the target antigen (N-acetylglucosaminyltransferase V), "lo" indicates that it is a low-affinity antibody, "mab" is an abbreviation for monoclonal antibody, and "tafenatox" is a reference to the Pseudomonas exotoxin.
Mechanism of Action
Nacolomab tafenatox works by binding to the N-acetylglucosaminyltransferase V antigen on the surface of cancer cells. Once bound, the toxin component of the drug is internalized by the cell, where it inhibits protein synthesis and ultimately leads to cell death.
Related Terms
- Monoclonal antibody
- Therapeutic antibody
- Pseudomonas exotoxin
- N-acetylglucosaminyltransferase V
- Protein synthesis
- Cell death
See Also
External links
- Medical encyclopedia article on Nacolomab tafenatox
- Wikipedia's article - Nacolomab tafenatox
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski